| 摘要: |
| 细胞程序性死亡因子1(programmed death-1,PD-1)及其配体1(programmed death- ligand 1,PD- L1)是一对共刺激分子,激活PD-1/PD-L1信号通路可抑制肿瘤特异性T细胞活性,有助于肿瘤细胞逃避免疫监视。而阻断该通路可以激活机体抗肿瘤免疫应答,抑制肿瘤细胞的生长。近年来,针对PD-1/PD-L1通路的免疫疗法在黑色素瘤的治疗中已取得显著效果。本文对PD-1/PD-L1通路在黑色素瘤中的表达调控、PD-1/PD-L1抑制剂在黑色素瘤治疗中的临床研究进行综述,讨论PD-1作为一种新的免疫疗法在临床的应用前景和不良反应。 |
| 关键词: 细胞程序性死亡因子1及其配体1信号通路 黑色素瘤 表达调控 临床研究进展 |
| DOI:10.13506/j.cnki.jpr.2021.01.008 |
| 基金项目:2017年度云南省地方本科高校(部分)基础研究专项立项项目(No.2017FH001-096);2017年度云南省昆虫生物医药研发重点实验室开放课题(No.EBR&D1706);中国西南药用昆虫及蛛形类资源开发利用协同创新中心2018年度开放课题(No.CIC1801) |
|
|
|
| Research progress of PD⁃1/PD-L1 pathway in melanoma |
| ZHANG Huazhu,LIU Xiaobo |
| (College of Pharmacy and Chemistry,Dali University,Dali 671000,China) |
| Abstract: |
| Programmed cell death 1 (PD-1) and its ligand (PD-L1) are a pair of co-stimulatory molecules, PD-1/PD-L1 pathway play an important role in the processes of production,development and escape.Activating the PD-1/PD-L1 pathway can inhibit tumor-specific T cell activity.It has been proved that PD-1 activation contributes to tumor immune escape and PD-1/PD-L1 inhibitors can enhance immune response,inhibit the growth of tumor cells.In recent years,great achievements have been got in melanoma about PD-1/PD-L1 inhibitors. This article reviewed the expression of PD-1/PD-L1 in melanoma and the clinical application of PD-1/PD-L1 inhibitors.Moreover,we further discussed the clinical application prospect and adverse reactions of PD-1/PD-L1 inhibitors. |
| Key words: PD-1/PD-L1 signal pathway Melanoma Expression regulation Clinical research progress |